What does Phamily Pharma do?

Phamily Pharma is a pharmacy in Aalst. Private Limited, started on 17 June 2004, 1 establishment.

What is the address of Phamily Pharma?

The registered office of Phamily Pharma is located at Boudewijnlaan 188 box A, 9300 Aalst.

Is Phamily Pharma still active?

Not as usual. The CBE lists Phamily Pharma with legal situation “Gerechtelijke ontbinding of nietigheid”.

Is Phamily Pharma registered on Peppol?

No, Phamily Pharma is currently not registered on the Peppol network.

What is the enterprise number of Phamily Pharma?

The enterprise number of Phamily Pharma is BE0865835955.

When was Phamily Pharma founded?

Phamily Pharma was founded on 17 June 2004.

Is Phamily Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Gerechtelijke ontbinding of nietigheid according to the CBE, started on 17 June 2004; 4 annual accounts filed, latest fiscal year 2022.

How much profit did Phamily Pharma make in 2022?

Phamily Pharma recorded a loss after taxes of € 81,087 in financial year 2022.

What is the revenue of Phamily Pharma?

As a small company, Phamily Pharma is not required to publish revenue in its annual accounts. In financial year 2022, its added value was € -51,341.

Phamily Pharma (Private Limited) - Aalst - BE0865835955

Dossier Phamily Pharma, printed on 1 October 2026 from databakkes.be/en/0865835955/phamily-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 1 of the last 4 fiscal years.
Tight liquidity NBB

Cash and receivables cover 43 % of short-term debt in 2022; threshold 65 %.
Legal situation KBO

Gerechtelijke ontbinding of nietigheid according to the CBE.

Financials

Financial year 2022

Phamily Pharma from Aalst, company number BE0865835955, closed financial year 2022 with a result of € -81,087 after tax. For that financial year Phamily Pharma recorded a gross margin of € -51,341 and equity of € -19,222. Compared with financial year 2021, the result moved from € 671 to € -81,087. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 30, 2023.

What it is worth Caution

€ -19,222

▼ € 81,087 vs 2021

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -81,087

▼ still € 671 profit in 2021

Profit after tax over the fiscal year.

Cash in the bank

€ 3,939

▼ 58% vs 2021

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -25,422.

People and assets in 2022

Vehicles and equipment

€ 23,367

▼ 12% vs 2021

Book value of vehicles, furniture and equipment.

Debts at end 2022

Bank debt ≈ 20 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 252,591

▼ 14% vs 2021

€ 12,444 is repaid this year. At this pace the long-term loan is gone in ≈ 20 years.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2019	2020	2021	2022	Change 2021 → 2022
Gross margin	€ 18,348 Gross margin 2019: € 18,348 First fiscal year in the series	€ -64,847 Gross margin 2020: € -64,847 ▼ € 83,195 vs 2019 (€ 18,348) Unfavourable step	€ 20,023 Gross margin 2021: € 20,023 ▲ € 84,870 vs 2020 (€ -64,847) Favourable step	€ -51,341 Gross margin 2022: € -51,341 ▼ € 71,365 vs 2021 (€ 20,023) Unfavourable step	▼ € 71,365
Profit after taxes	€ -3,998 Profit after taxes 2019: € -3,998 First fiscal year in the series	€ -86,034 Profit after taxes 2020: € -86,034 ▼ € 82,037 vs 2019 (€ -3,998) Unfavourable step	€ 671 Profit after taxes 2021: € 671 ▲ € 86,705 vs 2020 (€ -86,034) Favourable step	€ -81,087 Profit after taxes 2022: € -81,087 ▼ € 81,758 vs 2021 (€ 671) Unfavourable step	▼ € 81,758
Equity	€ 147,229 Equity 2019: € 147,229 First fiscal year in the series	€ 61,195 Equity 2020: € 61,195 ▼ 58% vs 2019 (€ 147,229) Unfavourable step	€ 61,865 Equity 2021: € 61,865 ▲ 1% vs 2020 (€ 61,195) Favourable step	€ -19,222 Equity 2022: € -19,222 ▼ € 81,087 vs 2021 (€ 61,865) Unfavourable step	▼ € 81,087
Total debts	€ 227,778 Total debts 2019: € 227,778 First fiscal year in the series	€ 369,045 Total debts 2020: € 369,045 ▲ 62% vs 2019 (€ 227,778) Unfavourable step	€ 479,490 Total debts 2021: € 479,490 ▲ 30% vs 2020 (€ 369,045) Unfavourable step	€ 429,078 Total debts 2022: € 429,078 ▼ 11% vs 2021 (€ 479,490) Favourable step	▼ 11%
Cash	€ 6,795 Cash 2019: € 6,795 First fiscal year in the series	€ 16,427 Cash 2020: € 16,427 ▲ 142% vs 2019 (€ 6,795) Favourable step	€ 9,414 Cash 2021: € 9,414 ▼ 43% vs 2020 (€ 16,427) Unfavourable step	€ 3,939 Cash 2022: € 3,939 ▼ 58% vs 2021 (€ 9,414) Unfavourable step	▼ 58%
Land & buildings	-	€ 107,695 Land & buildings 2020: € 107,695 First fiscal year in the series	€ 155,704 Land & buildings 2021: € 155,704 ▲ 45% vs 2020 (€ 107,695) Unchanged	€ 219,934 Land & buildings 2022: € 219,934 ▲ 41% vs 2021 (€ 155,704) Unchanged	▲ 41%
Retained profit	€ 141,029 Retained profit 2019: € 141,029 First fiscal year in the series	€ 54,995 Retained profit 2020: € 54,995 ▼ 61% vs 2019 (€ 141,029) Unfavourable step	€ 55,665 Retained profit 2021: € 55,665 ▲ 1% vs 2020 (€ 54,995) Favourable step	€ -25,422 Retained profit 2022: € -25,422 ▼ € 81,087 vs 2021 (€ 55,665) Unfavourable step	▼ € 81,087
Bank debt	€ 111,230 Bank debt 2019: € 111,230 First fiscal year in the series	€ 111,230 Bank debt 2020: € 111,230 Unchanged (€ 111,230) Unchanged	€ 294,603 Bank debt 2021: € 294,603 ▲ 165% vs 2020 (€ 111,230) Unfavourable step	€ 252,591 Bank debt 2022: € 252,591 ▼ 14% vs 2021 (€ 294,603) Favourable step	▼ 14%
Balance sheet total	€ 375,007 Balance sheet total 2019: € 375,007 First fiscal year in the series	€ 430,240 Balance sheet total 2020: € 430,240 ▲ 15% vs 2019 (€ 375,007) Unchanged	€ 541,355 Balance sheet total 2021: € 541,355 ▲ 26% vs 2020 (€ 430,240) Unchanged	€ 409,856 Balance sheet total 2022: € 409,856 ▼ 24% vs 2021 (€ 541,355) Unchanged	▼ 24%

Key figures of Phamily Pharma, fiscal years 2019 to 2022, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2023 has not been filed yet; it was expected before 31 July 2024.

What happened to Phamily Pharma?

What happened at Phamily Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Phamily Pharma is active according to the CBE. Legal situation: Gerechtelijke ontbinding of nietigheid.

Sep 30, 2023 New annual accounts for financial year 2022: loss of € 81,087 (▼ € 81,758 vs 2021). filed late Source: NBB ↗
Jul 16, 2004 New establishment in Erpe-Mere. KBO
Jun 17, 2004 Start of the company according to the CBE. KBO

In short

From € 3,998 loss in 2019 to € 81,087 loss in 2022.

Paid € 12,432 in corporate taxes since 2019.

Best year ever: 2021, with € 671 profit.

Original PDFs at the National Bank ↗

A new publication or filing at Phamily Pharma? We notify you, reason included.

Follow Phamily Pharma

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Establishments

Establishment units

Physical locations of this company

Registered office

Boudewijnlaan 188 box A

9300 Aalst

2.137.979.275

Kraaineststraat 35

9420 Erpe-Mere

Active since 16 July 2004

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

AFTER DRINKS

€ 46,124 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0865.835.955

VAT number

BE 0865.835.955

Registered office

Boudewijnlaan 188 bus A, 9300 Aalst

Names & denominations

Phamily Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Gerechtelijke ontbinding of nietigheid

Start date

17 June 2004

Peppol

Not registered

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗